Cytiva delivers modular biologics factory to Lonza


2021/1/14 16:02



AMERSHAM, United Kingdom, Jan. 14, 2021 /PRNewswire=KYODO JBN/ --


    - From site selection in Guangzhou Biopark to handover during the global

      pandemic, 17,000-square meter site was completed in less than two years

    - From Lonza's first manufacturing site for biologics in China, the

      healthcare leader will provide services and manufacturing needed to

      respond to growing global pharmaceutical needs

    - Site to become a strategic base in China for Lonza to provide CDMO

      services throughout Asia Pacific region


Cytiva, a global life sciences leader, has successfully completed another KUBio

installation, this time to global healthcare solutions provider Lonza, in

Guangzhou Biopark, China.  The high throughput modular biomanufacturing

facility will offer process development and manufacturing for Chinese companies

developing innovative medicines, as well as multinationals with manufacturing

requirements in China.


Photo -


Logo -


The 17,000-square-meter site includes 6,500 square meters of lab space and one

KUBio modular facility, and will enable quick ramp-up of antibody development

services and manufacturing, which are urgently needed to respond to market

needs for biologics, including mAbs and other complex proteins, in and for

China, and the rest of the world.  


The Chinese biologics sector's growth has outpaced global growth, particularly

in the last couple of years. According to estimates, the biologics market in

China has surged from just under USD 10 billion in 2012 to over USD 45 billion in 2020.[1]


Stefan Stoffel, Chief Operating Officer, Lonza, says: "The Cytiva team showed

great agility and speed in delivering this important site. With the KUBio and

FlexFactory single-use platform now ready for business, Lonza will be able to

respond to the great demand for innovative therapies in the current

environment, now and in the future."


Olivier Loeillot, Vice President, Cytiva, says: "In a rapidly-growing industry

with increasing needs for mAbs and other key biopharmaceuticals, this facility

demonstrates the strength of combining modular manufacturing with single-use

technologies.  Together, the KUBio and FlexFactory speed up delivery of

innovative therapeutics to patients who need them."


At the Guangzhou Biopark site, construction and supplies of building materials

were sometimes affected by lockdown and travel restrictions due to the COVID-19

pandemic. Still, the overall project was completed within its expected time range.  


This is Lonza's first manufacturing site for biologics in China. Lonza will

combine Cytiva's KUBio modular facility and single-use equipment to support its

Good Manufacturing Practice (GMP) manufacturing integrated with its own

platforms and expertise in development, including cell line construction and

process development. Scaling up production will be streamlined when needed

thanks to the flexibility in the design.


Guangzhou Biopark is also home to manufacturing sites for BeiGene and Akesobio,

where Cytiva also provided solutions. Cytiva has delivered 77 KUBio and

FlexFactory solutions to customers around the world.


For more information:

Read About KUBio ( )

Animation of Lonza site construction in Guangzhou ( )

Watch About the solution Cytiva provided for BeiGene ( )

Read the previous announcement with Lonza ( )


About Cytiva

Cytiva is a global life sciences leader with more than 7,000 associates across

40 countries dedicated to advancing and accelerating therapeutics. As a trusted

partner to customers that range in scale and scope, Cytiva brings speed,

efficiency and capacity to research and manufacturing workflows, enabling the

development, manufacture and delivery of transformative medicines to patients.


[1] Source:


SOURCE: Cytiva


CONTACT: In China, Iris Zhao, OR  In USA Colleen Connolly,